This week, you needed a scorecard to keep track of the biotechs that went, planned to go, or were still in line to go public.

To help make sense of it all, here’s a rundown of some key numbers pertaining to biotech IPOs. Also, here’s a link to a video interview with NECN from Wednesday afternoon, in which I try and make sense of it all in 60 seconds.

2: The number of Massachusetts biotechs originally scheduled to go public this week, according to Rennaissance Capital — Tokai Pharmaceuticals and Revo Biologics

1: Number of local biotechs that actually did hold IPOs (Revo postponed its offering).

14: Number of biotechs that have gone public so far this year.

$98 million: Amount raised by Tokai in Wednesday’s IPO.

58 percent: Amount of share price increase in Tokai’s first day of trading.

$1.1 billion: Amount raised by all 14 local biotech IPOs so far this year.

2: The number of biotech slated to go public next week, according to Renaissance Capital (Civitas Therapeutics and Revo Biologics)

$125 million: Total to be raised by next week’s two scheduled IPOs.

3: Number of Mass.-based biotechs that have filed to go public recently but haven’t yet (Proteon Therapeutics, Lantheus Medical and Eyegate Pharmaceuticals)

2: Number of Massachusetts based healthcare companies going public this week with the name, “Civitas.” (Boston-based Civitas Solutions, which provides services for disabled people and held a $198 million IPO Wednesday, is unrelated to Chelsea-based Civitas Therapeutics, which is scheduled to IPO next week).